<?xml version="1.0" encoding="UTF-8"?>
<p>The collected data were used to estimate the value of most of the model parameters, including diagnosis rate, pre-treatment disease progression rate, treatment initiation rate, loss to follow-up rate, viral load suppression (SVL, â‰¤500 copies/mL) and rebound (&gt;500/mL) rate (description on the derivation of parameter values from clinical data in 
 <bold>
  <xref ref-type="supplementary-material" rid="pone.0237433.s001">S1 Appendix</xref>
 </bold>). Annual number of reported new diagnoses and proportion of suspected non-local HIV infection were retrieved from surveillance epidemiological datasets. Parameters from overseas clinical trials, such as transmission risk, were referenced from literature.
</p>
